Looking for a Better Alternative to Chemotherapy for AL Amyloidosis

21:26
 
Share
 

Manage episode 198143706 series 49047
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Caelum Biosciences, a Fortress Biotech company, is a clinical-stage biotech developing treatments for rare and life-threatening diseases. It’s lead therapeutic in development is a novel antibody to treat patients with amyloid light chain amyloidosis, a rare disorder of the bone marrow that causes misfolded proteins to accumulate in tissue and organs throughout the body and cause damage. We spoke to Michael Spector, president and CEO of Caelum, about the company’s business model, its lead therapeutic, and how the competitive landscape for a rare disease therapy may shape development strategies.

215 episodes available. A new episode about every 7 days averaging 23 mins duration .